
RESEARCH



The use of transcutaneous electrical acupoint stimulation to reduce opioid consumption in patients undergoing off-pump CABG: a randomized controlled trial

Hui Zhang^{1†}, Lini Wang^{1†}, Ziyu Zheng¹, Jiange Han², Lin Li³, Wenlong Yao⁴, Zhijian Li⁵, Gang Luo¹, Baobao Gao¹, Jie Shen¹, Hailong Dong¹ and Chong Lei^{1*}

Abstract

Background High doses of long-acting opioids were used to facilitate off-pump coronary artery bypass grafting procedure, which may result in opioid-related adverse events after surgery. Transcutaneous electrical acupoint stimulation (TEAS) had been reported to be effective in reducing intraoperative opioids consumption during surgery. The aim of this study is to assess whether TEAS with difference acupoints can reduce the doses of opioid analgesics.

Methods This was a multicenter, randomized, controlled, double-blind trial. Patients underwent off-pump coronary artery bypass grafting under general anesthesia were enrolled. Eligible patients were randomly and equally grouped into sham acupuncture group (n = 105), regional acupoints combination group (n = 105), or distal-proximal acupoints combination group (n = 105) using a centralized computer-generated randomization system. Transcutaneous electrical acupoint stimulation was applied for 30 min before anesthesia induction. The primary outcome was the doses of sufentanil during anesthesia. Secondary outcomes included the highest postoperative vasoactive-inotropic scores within 24 h, intraoperative propofol consumption, length of mechanical ventilation, duration of cardiac care unit and postoperative hospital stay, incidence of postoperative complications, and mortality within 30 days after surgery.

Results Of the 315 randomized patients, 313 completed the trial. In the modified intention-to-treat analysis, the doses of sufentanil were 303.9 (10.8) µg in the distal–proximal acupoints group, significantly lower than the sham group, and the mean difference was -34.9 (-64.9 to -4.9) µg, p = 0.023. The consumption of sufentanil was lower in distal-proximal group than regional group (303.9 vs. 339.5), and mean difference was -35.5 (-65.6 to -5.5) μ g, p = 0.020. The distal-proximal group showed 10% reduction in opioids consumption comparing to both regional and sham groups. Secondary outcomes were comparable among three groups.

Conclusion Transcutaneous electrical acupoint stimulation with distal-proximal acupoints combination, compared to regional acupoints combination and sham acupuncture, significantly reduced sufentanil consumption in patients who underwent off-pump coronary artery bypass grafting surgery.

[†]Hui Zhang and Lini Wang contributed equally to this work.

*Correspondence: Chong Lei crystalleichong@126.com Full list of author information is available at the end of the article



© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Page 2 of 11

Keywords Transcutaneous electrical acupoint stimulation, Sufentanil, Off-pump coronary artery bypass grafting, Opioids consumption

Introduction

Off-pump coronary artery bypass grafting (CABG) is a minimally invasive procedure performed on a beating heart without cardiopulmonary bypass (CPB). Consequently, considerable hemodynamic fluctuations are common during the procedure (Go et al. 2013; Kurowicki et al. 2020). Traditionally, high doses of long-acting opioids were used to facilitate off-pump CABG procedure (Mathison et al. 2000). However, it may result in opioidrelated adverse events after surgery (Shu et al. 2013), with a documented incidence of up to 31.8% following CABG surgery (Barisin et al. 2007). Complications of gastrointestinal, central nervous system, or respiratory systems, pruritus, and urinary retention are the most common adverse events. Accumulating evidence supported the efficacy of multimodal opioid consumption strategies in reducing opioid consumption in cardiac surgery patients (Wick et al. 2017). The multimodal opioid consumption approaches are now recommended by the recent enhanced recovery after surgery (ERAS) guidelines for perioperative care in cardiac surgery (Engelman et al. 2019).

Transcutaneous electrical acupoint stimulation (TEAS) had been reported to be effective in reducing intraoperative opioids consumption and alleviate postoperative opioid-associated adverse events after surgery (Devlin and Roberts 2009). Moreover, mounting evidence has verified the protective effects of electroacupuncture in cardiac surgery, including attenuated myocardial injury (Bovill et al. 1984), lower incidence of postoperative cognitive dysfunction (Grunkemeier et al. 2007), and reduced duration of mechanical ventilation as well as the length of ICU stay (Baum et al. 2021). Combination of acupoints stimulation enhanced the efficacy of acupuncture, as synergistic effects were observed (Wolters et al. 1982). In lumbago rats, it was demonstrated that stimulation of distal-proximal combination of acupoints was more potent in raising the pain threshold than stimulation of regional acupoints combination (Taylor et al. 2019; Burkhart et al. 2010).

The purpose of this study was to compare the effects of TEAS on distal-proximal acupoints on intraoperative opioids consumption in patients undergoing off-pump CABG to those of regional acupoints combination or sham TEAS in multicenter settings, in order to testify the generalization of TEAS on the distal-proximal acupoints combination strategy. Because acupuncture was proven to have many other benefits, therefore, the endpoints such as hemodynamics, cardiac function, incidence of postoperative complications, and mortality were also included in this clinical trial.

Methods

Study design

We conducted an investigator-initiated, multicenter (five sites), randomized, controlled 3-arm trial in China. This study was approved by the Ethics Committee of The Xijing Hospital (KY20140420-X-1) and was registered with ClinicalTrials.gov (NCT02443220, date of registration: May 13, 2015). The study was registered prior to the first patient enrollment. Written informed consents were obtained from all participants before any experimental procedures. The first author attests to the accuracy and completeness of the data and for the fidelity and adherence of the trial to the protocol. The study is reported according to the Consolidated Standards of Reporting Trials (CONSORT) and the Standards for Reporting Intervention of Clinical Trials of Acupuncture (STRICTA) reporting guidelines.

Participants

Eligible study participants were patients with angiographically identified coronary artery disease scheduled for elective off-pump coronary artery bypass grafting surgery. Inclusion criteria included an American Society of Anesthesiologists score of less than IV and scheduled for first-time open-heart surgery. Exclusion criteria included urgent or emergent surgery; life expectancy < 1 year at the time of enrollment; hemodynamic instability, defined as systolic blood pressure < 90 mm Hg; supported with intra-aortic balloon pumping or ventricular assisted device; severe hepatic or renal dysfunction; severe systemic infection; contraindicated for TEAS, such as wound or infection at the selected acupoints; and suffering from nervous system diseases or with abnormal mental state.

Randomization and blinding

Eligible patients were randomly assigned with a 1:1:1 ratio to receive TEAS on distal-proximal acupoints, TEAS on regional acupoints or sham acupuncture, respectively. Randomization was performed through a secure randomization system with allocation concealment, using permuted block randomization, and stratified by accrual site.

The participants, outcome assessors, data managers, statisticians, and study monitors were blinded to the allocation. The clinical research coordinator (CRC) and acupuncture therapists were not blinded to group allocation. Study site investigators who were blinded to group allocation enrolled patient into study and collected clinical outcome data. The acupuncture therapist was the only unblinded investigator who opened the sealed envelope right before the anesthesia induction once the patient has consented to participate and then assigned the treatment group accordingly. The transcutaneous electrical acupoint stimulation (TEAS) intervention was administered by this acupuncture therapists in the pre-anesthesia preparation room. To ensure blinding during stimulation, the electronic acupuncture treatment instrument was securely encased in a box, concealing the stimulation current. Blinding was maintained until completion of analysis.

Interventions

Participants were recruited at the time of the decision for elective off-pump CABG surgery, and randomization occurred prior to the commencement of the surgery, after the patients entered into the pre-anesthesia preparation room. This maintained the allocation concealment to great extent. After randomization, the TEAS intervention was delivered by acupuncture therapists with at least 2 years of clinical experience.

The TEAS protocol was developed using a Delphi method. The treatment strategy (acupoints selection and frequency of electrical stimulation) was based on traditional Chinese medicine and consensus of clinical experts, and details are shown in Fig. S1 in Supplement. Participants in the distal-proximal acupoints combination group received acupuncture at Danzhong (CV17, located on the sternum) (Kurono et al. 2011; Li et al. 2021) and bilateral Hegu (LI4, located between the base of thumb and index fingers) (Guangjun et al. 2012, 2014). This combination of acupoints is believe to promote cardiac vagal function and enhance analgesia effects when stimulated. Participants in the regional acupoints combination group received acupuncture at Danzhong (CV17) and Juque (CV14, located at 6 cun above umbilicus) (Zou et al. 2018). This combination of acupoints is believe to reduce the heart rate and alleviate chest pain when stimulated.

After skin sterilization, conductive electrodes pads were pasted on the selected acupoints. The local acupoints were electrically stimulated with Hwato Electronic Acupuncture Treatment Instrument (model no. SDZ-V, Suzhou Medical Appliance Co., Ltd., Suzhou, China). The frequency appeared alternately at sparsedense wave (2/15 Hz), and the intensity gradually increased from 1 mA until the maximum current that the patient could tolerate. The maximum current that individual patients can tolerate was recorded. Appropriate stimulation on acupoints would induce a sensation of de qi, a composite local sensation of soreness, numbness, distension, heaviness, and other sensations. This is believed to be the essential component for the efficacy of acupuncture.

Patients in the sham group were administered sham acupuncture with electrodes pads pasted at CV17 and bilateral LI4 and connected to the electronic acupuncture treatment instrument, but without stimulation. TEAS sessions lasted 30 min prior to anesthesia induction. To blind the patients as much as possible, only patients who had never been exposed to TEAS were enrolled, and they were informed before acupuncture treatment that they may be sensitive or insensitive to TEAS. During the 30-min treatment process, the patients in sham group were asked if the stimulation was tolerable for three times to maximize the blinding. During stimulation, the electronic acupuncture treatment instrument is encased in a box; therefore, the stimulation current was covered and concealed. Stimulation-related adverse events were monitored and documented by the observation of researchers and the self-report of the patients.

Bolus injection of 0.03 mg/kg midazolam, target-controlled infusion (TCI) of propofol with plasma concentration of 1.0–2.0 ug/ml (Marsh model (Guggenberger et al. 2006)), and sufentanil with initial effect site concentration of 0.2 ng/ml (Gepts model (Kumar et al. 2017)) and increased 0.2 ng/ml per minute according to the change of bi-spectral index (BIS) were used for anesthesia induction. When patients lost consciousness, 0.6 mg/kg rocuronium was administered to facilitate endotracheal intubation. During operation, the BIS was maintained at 40 to 60. The effect site concentration of sufentanil was adjusted based on hemodynamics, BIS, and anesthesiologist experience, but propofol plasma concentration was kept steady.

Intraoperative hemodynamic parameters, including demographic characteristics, preoperative comorbidities, heart rate (HR), mean arterial pressure (MAP), BIS during the anesthesia, time of anesthesia and operation, and grafted numbers of coronary, were collected to describe diversity of the study population and the comparability of different intervention arms. HR, MAP, and BIS were recorded respectively at T0 (right before induction), T1 (loss of consciousness, LOS), T2 (right before intubation), T3 (3 min after intubation), T4 (incision), T5 (1 min after median sternotomy), T6 (after dissection of internal mammary artery), T7 (right before partial clamping of aorta), T8 (clamp releasing), T9 (5 min after reperfusion), T10 (closure of sternum), and T11 (ends of surgery).

Outcomes

The primary endpoint was the intraoperative total sufentanil consumption. Secondary endpoints were the highest vasoactive-inotropic scores (VIS) at 24 h after surgery, intraoperative propofol consumption, length of mechanical ventilation, length of CCU and postoperative hospital stay, incidence of serious complications within 30 days after surgery, and mortality at 30 days. The VIS was calculated based on the doses of dopamine, dobutamine, epinephrine, norepinephrine, vasopressin, and milrinone (Table S1 in Supplement). Serious complications included myocardial infarction, new onset of cardiac dysfunction (ejection fractions less than 35%, heart failure, or pericardial tamponade), delirium, shock, moderateto-severe acute kidney injury (Kidney Disease: Improving Global Outcomes stages 2 or 3), liver dysfunction (liver transaminase increased more than twice as much as preoperative baseline), pulmonary complications (pulmonary infection, atelectasis, or pleural effusion), infection, or sepsis.

Statistical analysis

The main hypothesis of this study was that stimulation of distal-proximal acupoints would lead to a reduction in intraoperative sufentanil consumption compared to regional acupoints stimulation and sham acupuncture. To test this hypothesis, two comparisons were made between the three intervention groups, and an alpha of 0.025 (two-sided) was used for the Bonferroni correction in the sample size calculation. A group difference of 45.4 µg of sufentanil consumption, corresponding to a 15% reduction, was predefined based on the results of a pilot study. To detect or reject this predetermined group difference with 80% power (two-sided tests; alpha = 0.025), 315 participants (105 per group) were required. Since the probability of missing or loss to follow-up in the primary endpoint was negligible, the sample size was not expanded. The sample size was performed using Stata version 15.1.

The descriptive statistics were summarized in the following manner where continuous variables were reported as means (standard deviations) or medians (inter-quartile ranges) where appropriate. Categorical variables were presented as frequencies (percentages). Normality was established via Shapiro–Wilk tests or Fisher exact tests accordingly.

The primary analysis was carried over the intention-to-treat population. Comparisons of the distal-proximal group were carried out against both the regional and sham groups. The mean differences were reported with 95% confidence intervals and *p*-values. The sufentanil consumption was demonstrated to be skewed to the left in the pilot study; the primary endpoint was thus further analyzed via the generalized linear model (GLM) over Gaussian family with log link. Covariates including weights, anesthesia duration, and study sites were adjusted for as potential confounding effects. Estimates of relative risk and marginal means were reported adjusting for weights, anesthesia duration, and study sites.

The secondary outcomes were compared in the similar manner; the distal-proximal group was compared against both the regional and sham groups respectively. The standardized mean differences were presented with 95% confidence intervals. The trends of the hemodynamic measurements were shown using smoothed lines via spline curves. Further explorations of behavior of hemodynamic measurements were done via log-Gaussian generalized linear models adjusting for the baseline information, group indicator, time points, and grouptime interactions. The ICU and postoperative hospital stays were evaluated via Cox regression taking account of group indicator (distal-proximal group as reference category) and central effects (referenced on center 1).

The robustness of the study results was governed by the following sensitivity analyses. The primary endpoint was conducted in the per-protocol population including only those participants who completed the treatment originally allocated. A generalized linear model with additional center effect adjusted for was also used to re-estimate the effects of intervention removing the impacts clustered within each center.

The post hoc subgroup analyses further investigated how different groups of patients react to the intervention assigned, e.g., how different gender is affected. The following subgroups were considered: sex, age (<65 years or \geq 65 years), participating sites, levels of NYHA, clamping aorta or not, and European System for Cardiac Operative Risk Evaluation (EuroSCORE I, <4 or \geq 4). No primary outcomes were missing. Missingness in hemodynamic parameters were imputed using the last observation carried forward method. Multiple imputation was used for other missing data.

All statistical analyses were performed at 5% significance level using IBM SPSS statistics 26 or R version 4.1.0 (www.r-project.org). For the primary endpoint, Bonferroni approach was adopted for multiple comparisons (alpha = 0.025) for each independent comparison of distal-proximal acupoints stimulation vs sham acupuncture and distal-proximal acupoints stimulation vs regional acupoints stimulation. Analyses for secondary or post hoc analyses were not adjusted; therefore, they were interpreted as exploratory.

Results

A total of 337 candidates were screened for eligibility from October 2017 to September 2018. Of them, 22 were excluded due to ineligibility for various reasons (details see Fig. 1), leaving 315 patients eligible for randomized (105 in each group, Fig. 1). The number of dropouts or protocol violation at each stage and the number assessed for primary end point are presented in Fig. 1. Finally, 313 patients were included in modified intention-to-treat analysis, whereas 306 patients were included in the per protocol analysis. There was no substantial difference in the dropout rates among the groups. The last followup visit was completed on August 15, 2019. All subjects completed outcome measurements at 30 days.

Patient baseline characteristics are demonstrated in Table 1 and were balanced among groups. There were 70 women (22.2%) and 245 men (77.8%) with a mean age of 61.7 (8.6) years included in the study. The delivery of treatment and compliance with the intervention were evenly distributed among groups.

Primary outcome

The primary end point was analyzed in the modified intention-to-treat set and per protocol population (Table 2). In the modified intention-to-treat set, the total sufentanil consumption in distal–proximal, regional, and sham groups were 303.94 (10.80), 339.49 (10.87), and 338.84 (10.87) µg, respectively (Table S2 in Supplement). The total sufentanil consumption was reduced in distal-proximal acupoints stimulation group as compared with regional acupoints stimulation group (mean difference: -35.54 μg; 95% *CI*, -65.56 to -5.53 μg; *p*<0.025) and sham group (mean difference: - 34.89 µg; 95% CI, -64.93 to -4.85 µg; p < 0.025) (Table 2 and Table S3 in Supplement). This pattern of findings for the primary outcome was unchanged in the per-protocol population (Table 2 and Table S3 in Supplement). The generalized linear model with log-Gaussian family also guaranteed such effect; upon adjustment of weight and anesthesia times, the effect distal-proximal group still shows the significant lowest effect on sufentanil consumption (Figure S2 in Supplement). The estimates are robust as they are consistent on adjustment of central effects (Figure S3 in Supplement). The contour plot of Fig. 2 shows the relationship between the time, group, and the concentration of sufentanil. The concentration of sufentanil during anesthesia was lower in distal-proximal group.

Secondary and exploratory outcomes

For the secondary outcomes, no significant differences were seen among three groups (Table 3). The intraoperative propofol consumption was comparable among the patients in three groups. Length of mechanical ventilation, duration of cardiac care unit, and postoperative




Fig. 1 Flowchart showing trial group assignments, loss of follow-up, treatment completion, and protocol deviation. Eligible for randomized, 313 patients were included in modified intention-to-treat analysis, whereas 306 patients were included in the per protocol analysis

Table 1 Baseline characteristics of randomized population

| Baseline characteristics | | Regional group n=105 | Distal–proximal group n=105 | Sham group n=105 |
|---|----------------|-------------------------|--------------------------------|----------------------|
| Age (years) | | 64.0 (57.5, 68.0) | 63.0 (55.0, 67.0) | 61.0 (57.0–67.0) |
| Female, <i>n</i> (%) | | 22 (21.0) | 23 (21.9) | 25 (23.8) |
| BMI (kg/m ²⁾ | | 25.8 (23.3, 28.2) | 25.5 (23.6, 27.4) | 25.3 (23.3, 27.4) |
| NYHA, n (%) | | | | |
| II | | 62 (59.0) | 56 (53.3) | 59 (46.7) |
| III | | 43 (41.0) | 49 (46.7) | 45 (43.3) |
| EuroSCORE I | | 4.0 (2.0, 5.0) | 4.0 (3.0, 5.0) | 4.0 (2.75, 5.0) |
| Previous MI, n (%) | | 34 (33.0) | 34 (32.4) | 23 (22.1) |
| Uncorrected valvular heart disease, n (%) | | 30 (28.6) | 34 (32.4) | 34 (32.4) |
| Previous stock, n (%) | | 23 (21.9) | 20 (19.0) | 22 (21.0) |
| Diabetes, n (%) | | 38 (36.2) | 41 (39.0) | 44 (41.9) |
| Hypertension, n (%) | | 77 (73.3) | 67 (63.8) | 73 (69.5) |
| Dyslipidemia, n (%) | | 14 (13.3) | 25 (23.8) | 17 (16.2) |
| Smoking, <i>n</i> (%) | Never | 38 (36.2) | 34 (32.3) | 36 (34.3) |
| | Within 12 m | 46 (43.8) | 51 (48.6) | 43 (41.0) |
| | More than 12 m | 19 (18.1) | 20 (19.0) | 24 (22.9) |
| Previous cardiac surgery, n (%) | | 6 (5.7) | 1 (1.0) | 6 (5.7) |
| Abnormal ECG, <i>n</i> (%) | | 85 (81.0) | 86 (81.9) | 91 (86.7) |
| Intraoperative characteristics | | | | |
| Length of operation (minutes) | | 202.0 (148.0, 260.0) | 210.0 (145.0, 290.0) | 210.0 (150.0, 275.5) |
| Length of anesthesia (minutes) | | 252.0 (212.7, 308.1) | 256.0 (189.0, 298.8) | 233.0 (174.3, 283.6) |
| Grafted numbers of coronary | | 3.0 (2.0, 3.0) | 3.0 (2.0, 4.0) | 3.0 (2.0, 3.0) |

Values are median (IQR), unless stated otherwise. Abbreviations: IQR, interquartile range; BMI, body mass index; MI, myocardial infraction; NYHA, New York Heart Association classification; EuroSCORE, European System for Cardiac Operation Risk Evaluation; LVEF, left ventricle ejection fraction

| Table 2 Primary outcome measurements o | f modified intention to treat set and per protoco | l set |
|--|---|-------|
|--|---|-------|

| Group | Regional group | Distal–proximal group | Sham group | Distal–proximal vs regi | onal | Distal-proximal vs sham | | |
|-------------------------|----------------|--------------------------|--------------|-----------------------------|-------|-----------------------------|-------|--|
| MITT, n=313 | n=104 | n=105 | n=104 | Mean difference (95% Cl) | p* | Mean difference (95% Cl) | p* | |
| Dose of sufentanil (µg) | 339.5 (10.9) | 303.9 (10.8) | 338.8 (10.9) | -35.5 (-65.6,-5.5) | 0.020 | -34.9 (-64.9, -4.9) | 0.023 | |
| PP, <i>n</i> = 306 | n=102 | n=104 | n = 100 | | | | | |
| Dose of sufentanil (µg) | 338.6 (11.0) | 303.6 (10.9) | 339.4 (11.1) | -35.0 (-65.4, -4.6) | 0.024 | -35.9 (-66.4, -5.3) | 0.021 | |

Abbreviations: SE standard error, MITT modified intention-to-treat analysis, PP per protocol

Values are marginal mean (SE)

^{*} Multiple pairwise comparisons were adjusted by Bonferroni approach with p < 0.025 considered as significant

hospital stays were not significantly different across the three groups. Pulmonary complications, infection, liver dysfunction, and acute kidney injury were the most common postoperative complications, with incidences ranging from 10 to 20%. Specifically, the incidences of all complications occurred statistically equivalently across three groups. One patient in regional and distal-proximal group (0.98% and 0.96%, respectively) and three patients (2.88%) in sham group died within 30 days after surgery. No significance in mortality differences was found. Despite no significant interaction was found between intervention and time for MAP, HR, and BIS and concentration of sufentanil (Figs. S3 and S4 in Supplement), the tendency of differences can still be seen in MAP, HR, and concentration of sufentanil.

Subgroups

The interactions in relation to the treatment effects of distal-proximal acupoints stimulation vs regional acupoints stimulation and distal-proximal acupoints




Fig. 2 Surface plot of concentration sufentanil vs time group. The contour plot shows the relationship between the time, group, and the concentration of sufentanil. The concentration of sufentanil during anesthesia was lower in distal–proximal group

stimulation vs sham stimulation on consumption of sufentanil were investigated in post hoc subgroups. None of the subgroups showed significant interactions. However, some subgroup effects were shown significant. For example, the sufentanil consumption effect of distal– proximal group was more prominent when compared with regional and sham groups in male and patients whose NYHA classification was III and underwent surgery in center 1 (Fig. 3, Tables S4 and S5 in Supplement). No other subgroup effects were found significant in the specified stratum, including age, aorta clamping, or Euro-Score I.

Adverse events and quality of blinding

Stimulation-related adverse events include continuous post-electrostimulation sensation and skin numbness, allergic reaction, redness, swelling, pain, or other injury on the skin during acupuncture treatment. There were no stimulation-related adverse events or other equipment malfunction reported in any of the three groups during the treatment. No serious adverse events were identified that was TEAS related.

Discussion

In this multicenter randomized controlled trial, we investigated the effect of TEAS on opioid consumption in patients scheduled for off-pump CABG surgery under total intravenous anesthesia. Comparing with regional acupoints combination and sham acupuncture, TEAS with distal-proximal acupoints combination significantly reduced total sufentanil consumption. The study testified the opioid consumption effect of TEAS with different acupoints combination in patients undergoing off-pump CABG surgery in a multicenter setting. The

| Group | Regional group n=104 | Distal–proximal group n=105 | Sham group n=104 | Distal–proximal vs regional | Distal-proximal vs sham |
|---|-------------------------|--------------------------------|----------------------|--------------------------------|-------------------------|
| | | | | SMD (95% C/) | SMD (95% CI) |
| Postoperative VIS at 24 h | 3.5 (2.0, 4.9) | 4.5 (2.0, 5.0) | 4.5 (2.7, 5.9) | 0.22 (-0.05, 0.50) | 0.13 (-0.14, 0,40) |
| Dosage of propofol (mg) | 561.0 (359.5, 847.5) | 581.5 (383.5, 923.5) | 470.5 (274.8, 727.3) | 0.00 (-0.27, 0.27) | 0.22 (-0.06, 0.49) |
| Length of mechanical ventilation (h) | 16.3 (8.8, 19.0) | 15.8 (7.8, 19.1) | 15.9 (10.8, 19.9) | 0.12 (-0.15, 0.39) | 0.02 (- 0.25, 0.29) |
| Length of CCU stays (h) | 40.0 (22.8, 46.0) | 41.0 (27.8, 45.1) | 41.0 (25.3, 67.8) | 0.05 (-0.23, 0.32) | 0.19 (-0.08, 0.46) |
| Length of postoperative hospital stays (day) | 9.0 (7.0, 11.0) | 9.0 (7.0, 12.0) | 9.0 (8.0, 11.8) | 0.17 (-0.10, 0.45) | 0.02 (-0.26, 0.29) |
| Postoperative complication | ons, <i>n</i> (%) | | | | |
| Myocardial infarction | 19 (18.3) | 27 (25.7) | 19 (18.3) | 0.18 (-0.09, 0.46) | 0.16 (-0.12, 0.43) |
| Cardiac dysfunction | 2 (1.9) | 4 (3.8) | 5 (4.8) | 0.16 (-0.11, 0.43) | 0.00 (-0.27, 0.28) |
| Delirium | 0 (0.0) | 1 (1.0) | 3 (2.9) | 0.14 (-0.13, 0.41) | 0.15 (-0.13, 0.42) |
| Stroke | 0 (0.0) | 2 (1.9) | 1 (1.0) | 0.20 (-0.08, 0.47) | 0.08 (-0.20, 0.35) |
| Acute kidney injury | 10 (9.6) | 12 (11.4) | 10 (9.6) | 0.06 (-0.22, 0.34) | 0.06 (-0.21, 0.34) |
| Liver dysfunction | 10 (9.6) | 19 (18.1) | 15 (14.4) | 0.25 (-0.02, 0.53) | 0.10 (-0.17, 0.38) |
| Pulmonary complica- tion | 19 (18.3) | 21 (19.0) | 13 (12.5) | 0.04 (-0.24, 0.31) | 0.20 (-0.08, 0.48) |
| Infection | 20 (19.2) | 21 (19.0) | 18 (17.3) | 0.02 (-0.26, 0.29) | 0.06 (-0.22, 0.33) |
| Other complication | 2 (1.9) | 3 (2.9) | 0 (0.0) | 0.14 (-0.14, 0.41) | 0.06 (-0.22, 0.33) |
| Mortality within 30 days, <i>n</i> (%) | 1 (1.0) | 1 (1.0) | 3 (2.9) | 0.00 (-0.27, 0.28) | 0.09 (-0.19, 0.36) |

Table 3 Second outcomes were analyzed in modified intention-to-treat analysis

Abbreviations: SMD standard mean difference, calculating as difference in mean outcome between groups divided by standard deviation of outcome among participants, VIS vasoactive-inotropic scores, CCU cardiac care unit

Values are median (IQR), unless stated otherwise

| Plan A | | | | | Plan B | | | | |
|---------------------------|-------------|------------|-------------------|-------------------|--------------------|---------------|---------------------------------------|-------------------|-------------------|
| Variable Gender | Count (Perc | ent) | RR (95%CI) | P 0.841 | Variable Gehder | Count (Percer | nt) | RR (95%CI) | P 0.238 |
| Female | 53 (25.4) | | 1.14 (0.89, 1.49) | 0.307 | Female | 40 (19.1) | | 0.98 (0.79, 1.20) | 0.828 |
| Male | 156 (74.6) | | 1.12 (1.00, 1.25) | 0.058 | Male | 169 (80.9) | - | 1.13 (1.02, 1.25) | 0.02 |
| Age | | | | 0.517 | Age | | | | 0.795 |
| < 65 | 131 (62.7) | | 1.09 (0.96, 1.25) | 0.162 | < 65 | 123 (58.9) | - | 1.13 (1.00, 1.27) | 0.052 |
| ≥ 65 | 78 (37.3) | | 1.20 (1.00, 1.43) | 0.058 | ≥ 65 | 86 (41.1) | - | 1.11 (0.97, 1.26) | 0.153 |
| Center | | | | 0.27 | Center | | | | 0.084 |
| 1 | 71 (34) | | 1.03 (0.91, 1.16) | 0.608 | 1 | 72 (34.4) | H II H | 1.17 (1.05, 1.30) | 0.005 |
| 2 | 74 (35.4) | | 1.11 (0.94, 1.32) | 0.238 | 2 | 71 (34.0) | | 1.04 (0.91, 1.20) | 0.607 |
| 3 and 4 | 32 (15.3) | | 1.13 (0.85, 1.48) | 0.408 | 3 and 4 | 31 (14.8) | + - | 0.96 (0.80, 1.15) | 0.63 |
| 5 | 32 (15.3) | | 1.39 (0.95, 2.14) | 0.106 | 5 | 35 (16.7) | · · · · · · · · · · · · · · · · · · · | 1.31 (0.91, 1.94) | 0.159 |
| NYHA | | | | 0.632 | NYHA | | | | 0.123 |
| I | 23 (11) | | 1.21 (0.84, 1.84) | 0.347 | 1 | 18 (8.6) | | 0.93 (0.76, 1.15) | 0.546 |
| Ш | 95 (45.5) | + - | 1.06 (0.92, 1.22) | 0.418 | П | 97 (46.4) | - | 1.09 (0.94, 1.28) | 0.238 |
| III | 91 (43.5) | | 1.13 (0.98, 1.28) | 0.094 | Ш | 94 (45) | 1 8 4 | 1.17 (1.06, 1.31) | 0.004 |
| Clamped partial aor | | | | 0.372 | Clamped partial a | aorta | | | 0.363 |
| No | 60 (28.7) | | 0.99 (0.88, 1.13) | 0.929 | No | 67 (32.1) | - - | 1.17 (1.03, 1.34) | 0.019 |
| Yes | 149 (71.3) | | 1.13 (1.00, 1.27) | 0.059 | Yes | 142 (67.9) | | 1.06 (0.96, 1.19) | 0.249 |
| EuroSCORE | | | , | 0.95 | EuroSCORE | | | | 0.708 |
| < 4 | 134 (64.1) | | 1.13 (0.99, 1.28) | 0.064 | < 4 | 143 (68.4) | | 1.11 (0.99, 1.23) | 0.066 |
| ≥ 4 | 75 (35.9) | | 1.13 (0.94, 1.36) | 0.201 | ≥ 4 | 66 (31.6) | - | 1.07 (0.92, 1.23) | 0.376 |
| | | 0 1 2 | 3 | | | · · / | 1 2 | 3 | |
| Distal-proximal | | | | | | | Distal-proximal | | |

Fig. 3 Subgroup analysis of total doses of sufentanil with GLM in modified intention-to-treat population. None of the subgroups showed significant interactions. Plan A, subgroup analysis of total doses of sufentanil with GLM between distal–proximal group and regional group. Plan B, subgroup analysis of total doses of sufentanil with GLM between distal–proximal group. The sufentanil consumption effect of distal–proximal group was more prominent when compared with regional and sham groups in male and patients whose NYHA classification was III and underwent surgery in center 1

study provides evidences for the acupoints selection on how the TEAS or acupuncture drug balanced anesthesia should be applied to clinical practice.

TEAS with distal-proximal acupoints combination was shown to effectively reduce the dose of opioids as compared with regional acupoints combination and sham acupuncture. These findings indicate that the opioidsparing effect of TEAS is associated with selection of acupoints. As previously established, acupuncture has been increasingly used to assist anesthesia during surgeries, thanks to its potent analgesic effects (Wang et al. 2014; Zhou et al. 2011; Zhang et al. 2014).

Different acupoints combination determines the clinical efficacy of acupuncture (Xuefen et al. 2020; Du et al. 2022). For example, the regional acupoints combination of ZhongFu (LU1), LieQue (LU7), and XiMen (PC4) acupoints for electroacupuncture started 15-20 min prior to surgical incision to the end of cardiopulmonary bypassassisted cardiac surgery and only consumed 13% of the fentanyl required in the control group without electroacupuncture (Zhou et al. 2011). Similarly, the opioids consumption in the distal-proximal group in our study was shown to have reduced by approximately 10% comparing to the sham group. Empirical evidence of traditional Chinese medicine and clinical experiences both suggested that stimulation on distal-proximal acupoints combination (acupoints distal and adjacent to lesion position) has synergistic effects and is more potent than regional acupoints combination (Xuefen et al. 2020; Du et al. 2022; Wu et al. 2020). In a randomized controlled trial, TEAS with distal-proximal acupoints combination of Hegu (LI4), Neiguan (PC6), and Zusanli (ST36) for 30 min before anesthesia reduced remifentanil requirement for 39% in patients undergoing sinusotomy as compared with no TEAS (Wang et al. 2014). The reason behind this could be as suggested by accumulating evidences on the analgesia effect of acupuncture; it is mediated by reducing the excitability of sympathetic nervous, inhibiting the production of catecholamine, and increasing the levels of adrenocorticotropic hormone, cortisol, endothelin, and adenosine (Visvardis et al. 2004; Risch et al. 2001). Our study further contributes to the experience by showing a significant opioids consumption reduction in the distal-proximal group comparing to the regional group by approximately 10%.

The study has not found significant results in the secondary outcomes. Although previous studies have reported that the incidence of postoperative pulmonary complications, length of ICU stay, and the overall medical costs were reduced (Zhang et al. 2014), this should not establish a major violation as the sample size calculated based on the primary outcome does not provide sufficient power for solid evidence in these secondary outcomes. Tendencies of reduction comparing to sham group were also shown in length of CCU stays in our study. Moreover, length of mechanical ventilation, length of postoperative hospital stays, cardiac dysfunction, delirium, and other complications all showed reduction tendencies comparing to the sham group. Further investigations shall be conducted to draw firm evidences in these aspects.

The study has also shown tendency that different subgroups benefit differently. For example, males, over 65 years old group, the higher NYHA group, and aorta partial clamped group tend to benefit more. This may be explained as these groups are commonly administrated less opioid dosages as the body functions are sensitive to drugs prescribed and treatment given. The temporal trends in hemodynamic suggested possible diversions among groups in different time points, but firm conclusions still request designs with larger sample sizes and more precise records.

Up until now, very few studies have compared the effects of distal-proximal acupoints combination to any other acupoints combination strategies, to the best of our knowledge. Therefore, our study fills the gap of evidencebased support to the benefit of TEAS on distal-proximal acupoints combination to the regional acupoints combination via a sophisticated RCT in multiple centers. The blinding is also carefully concerned and conducted with the best effort. For example, all patients were asked if the stimulation was tolerable for several times during TEAS treatment process. However, there are several limitations in our study. First, the use of electrical stimulation may make it difficult to separate activation of acupoints from non-acupoints since the electrical current spreads between acupoints. This means that the anestheticsparing effects of TEAS may be blunt as they rely highly on the accuracy of locations of acupoints. Second, the length of the TEAS intervention was short. This may be the potential explanation for failure to detect significant statistical differences as refer to the postoperative complications or mortality among three groups in our study. Third, although the patients were blinded to the group allocation in this study, the blinding assessment was not conducted when the intervention finished. We do not take this as a major disadvantage to our study due to methods taken during procedures (e.g., asking patients about current described above), and the primary outcome being the intraoperative opioid consumption limits the subjective bias injected from the patients. Also, the ultimate goal of this research is to find the optimal acupoints combination in patients undergoing off-pump CABG, and the previous study findings suggested that the sufentanil-sparing effect in distal-proximal acupoints combination group was significantly better than

both the regional and sham group. No comparison was made between the regional acupoints combination group and sham group. Fourth, our initial estimate was a 15% reduction in the dosage of sufentanil when using a combination of distal-proximal acupoints. However, the actual reduction achieved was only 10%. While a 10% reduction in opioid dosage may demonstrate statistical significance, determining its clinical significance would require careful consideration within the specific clinical context. Additionally, our investigation did not identify any evidence of opioid-related side effects such as postoperative nausea and vomiting, respiratory depression, or pruritus. It is important to note that our study included patients undergoing off-pump coronary artery bypass grafting (CABG), who were subsequently transferred to the coronary care unit (CCU) for further evaluation and treatment. Therefore, complete information on all shortterm opioid side effects is not available.

Conclusion

In this multicenter, randomized controlled trial, significant reduction of intraoperative opioids consumption was observed in TEAS with distal-proximal acupoints combination compared to regional acupoints combination in off-pump CABG surgery. Potential benefit populations are pointed out, but future studies are needed for firm conclusions. The future study should also focus on the effects of TEAS with distal-proximal acupoints combination on long-term outcome of patients undergoing cardiac surgery.

Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s13741-024-00427-2.

Additional file 1: Figure S1. Location of the Acupoints. Figure S2. Estimate total dose of sufentanil between three groups. Figure S3. Estimate total dose of sunfentanil between three groups. Figure S4. MAP, HR, BIS and Concentration of sufentanil during anesthesia. Figure S5. Interaction between intervention and time for MAP, HR, BIS and Concentration of sufentanil. Table S1. The version of vasoactive-inotropic score (VIS). Table S2. Marginal Means of total sufentanil consumption. Table S3. Difference (95% CI) of total sufentanil consumption among three groups. Table S4. Subgroup analysis of total sufentanil consumption with GLM between distal-proximal group and regional group. Table S5. Subgroup analysis of total sufentanil group and sham group.

Acknowledgements

We thank all the patients who agreed to participate in our clinical trial and the staff who have taken part in our trial.

Authors' contributions

Chong Lei contributed to the conception and design of the study. Huizhang, Jie Shen, Jiange Han, Lin Li, Wenlong Yao, Zhijian Li, Lini Wang, Baobao Gao contributed to the acquisition of data; Lini Wang, Ziyu Zheng and Gang Luo contributed to the analysis and interpretation of data. Lini Wang, Hui Zhanf,

Ziyu Zheng, Gang Luo and Chong Lei contributed to prepare and drafting the manuscript. Chong Lei contributed to reviewing the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (NNSFC, No. 81970448) and University and Hospital Funded Clinical Research Projects (No. XJZT21L17).

Availability of data and materials

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

The trial has been approved by the Ethics Committee of The Xijing Hospital (KY20140420-X-1) and was registered with ClinicalTrials.gov (NCT02443220). Written informed consents were obtained from all participants before any experimental procedures.

Consent for publication

Competing interests

All authors approved the final manuscript and the submission to this journal.

The authors declare no competing interests.

Author details

¹ Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China. ²Department of Anesthesiology, Tianjin Chest Hospital, Tianjin, China. ³Department of Anesthesiology, General Hospital of Northern Theater Command, Shenyang, China. ⁴ Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. ⁵Department of Anesthesiology, The Second Xiangya Hospital, Central South University, Changsha, China.

Received: 26 December 2023 Accepted: 22 June 2024 Published online: 05 July 2024

References

- Barisin S, Sakić K, Goranović T, Barisin A, Sonicki Z. Perioperative blood pressure control in hypertensive and normotensive patients undergoing off-pump coronary artery bypass grafting: prospective study of current anesthesia practice. Croat Med J. 2007;48(3):341–7.
- Baum MK, Tamargo JA, Ehman RL, et al. Heroin use is associated with liver fibrosis in the Miami Adult Studies on HIV (MASH) cohort. Drug Alcohol Depend. 2021;220:108531.
- Bovill JG, Sebel PS, Stanley TH. Opioid analgesics in anesthesia: with special reference to their use in cardiovascular anesthesia. Anesthesiology. 1984;61(6):731–55.
- Burkhart CS, Dell-Kuster S, Gamberini M, et al. Modifiable and nonmodifiable risk factors for postoperative delirium after cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2010;24(4):555–9.
- Devlin JW, Roberts RJ. Pharmacology of commonly used analgesics and sedatives in the ICU: benzodiazepines, propofol, and opioids. Crit Care Clin. 2009;25(3):431-449 vii.
- Du L, Song XJ, Li ZW, Liao LX, Zhu YH. Combined use of Shenmen (HT 7) and Sanyinjiao (SP 6) to improve the anxiety and depression in patients with insomnia: a randomized controlled trial. Zhongguo Zhen Jiu. 2022;42(1):13–7.
- Engelman DT, Ben Ali W, Williams JB, et al. Guidelines for perioperative care in cardiac surgery: enhanced recovery after surgery society recommendations. JAMA Surg. 2019;154(8):755–66.
- Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–245.

- Grunkemeier DM, Cassara JE, Dalton CB, Drossman DA. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol. 2007;5(10):1126–39 quiz 1121-1122.
- Guangjun W, Yuying T, Shuyong J, Wenting Z, Weibo Z. Bilateral Hegu acupoints have the same effect on the heart rate variability of the healthy subjects. Evid Based Complement Alternat Med. 2014;2014: 106940.
- Guggenberger H, Schroeder TH, Vonthein R, Dieterich HJ, Shernan SK, Eltzschig HK. Remifentanil or sufentanil for coronary surgery: comparison of postoperative respiratory impairment. Eur J Anaesthesiol. 2006;23(10):832–40.
- Guangjun W, Yuying T, Shuyong J, Tao H, Weibo Z. Change of blood perfusion in Hegu acupoint after contralateral Hegu acupoint was stimulated. J Altern Complement Med. 2012;18(8):784–8.
- Kumar K, Kirksey MA, Duong S, Wu CL. A review of opioid-sparing modalities in perioperative pain management: methods to decrease opioid use postoperatively. Anesth Analg. 2017;125(5):1749–60.
- Kurono Y, Minagawa M, Ishigami T, Yamada A, Kakamu T, Hayano J. Acupuncture to Danzhong but not to Zhongting increases the cardiac vagal component of heart rate variability. Auton Neurosci. 2011;161(1–2):116–20.
- Kurowicki A, Borys M, Zurek S, et al. Remifentanil and sevoflurane based anesthesia combined with bilateral erector spinae plane block in patients undergoing off-pump coronary artery bypass graft surgery. Wideochir Inne Tech Maloinwazyine. 2020;15(2):346–50.
- Li DH, Xie J, Ren YL, et al. Effectiveness and safety of acupoint application of Guan Xin Su He Pill () for patients with chronic stable angina pectoris: a multi-center, randomized controlled trial. Chin J Integr Med. 2021;27(11):838–45.
- Mathison M, Edgerton JR, Horswell JL, Akin JJ, Mack MJ. Analysis of hemodynamic changes during beating heart surgical procedures. Ann Thorac Surg. 2000;70(4):1355–60 discussion 1360-1351.
- Risch L, Blumberg A, Huber AR. Assessment of renal function in renal transplant patients using cystatin C. A comparison to other renal function markers and estimates. Ren Fail. 2001;23(3–4):439–48.
- Shu A, Zhan L, Fang H, et al. Evaluation of remifentanil anesthesia for off-pump coronary artery bypass grafting surgery using heart rate variability. Exp Ther Med. 2013;6(1):253–9.
- Taylor RG, Budhram A, Lee DH, Mirsattari SM. Opioid-associated amnestic syndrome observed with fentanyl patch use. CMAJ. 2019;191(12):E337-e339.
- Visvardis G, Griveas I, Zilidou R, et al. Glomerular filtration rate estimation in renal transplant patients based on serum cystatin-C levels: comparison with other markers of glomerular filtration rate. Transplant Proc. 2004;36(6):1757–9.
- Wang H, Xie Y, Zhang Q, et al. Transcutaneous electric acupoint stimulation reduces intra-operative remifentanil consumption and alleviates postoperative side-effects in patients undergoing sinusotomy: a prospective, randomized, placebo-controlled trial. Br J Anaesth. 2014;112(6):1075–82.
- Wick EC, Grant MC, Wu CL. Postoperative multimodal analgesia pain management with nonopioid analgesics and techniques: a review. JAMA Surg. 2017;152(7):691–7.
- Wolters EC, van Wijngaarden GK, Stam FC, et al. Leucoencephalopathy after inhaling "heroin" pyrolysate. Lancet. 1982;2(8310):1233–7.
- Wu XF, Zheng XN, Wang Y, et al. Acupuncture at acupoints along the meridians for primary insomnia: a multi-center randomized controlled trial. Zhongguo Zhen Jiu. 2020;40(5):465–71.
- Xuefen W, Ping L, Li L, Xiaoli C, Yue Z. A clinical randomized controlled trial of acupuncture treatment of gastroparesis using different acupoints. Pain Res Manag. 2020;2020:8751958.
- Zou YF, Ma MZ, Zhao Z, et al. Effect of herbal-cake-separated moxibustion on blood lipid levels and expression of hepatic PPARγ and SR-B 1 proteins and genes in hyperlipidemia atherosclerosis rabbits. Zhen Ci Yan Jiu. 2018;43(2):86–91.
- Zhang Q, Gao Z, Wang H, et al. The effect of pre-treatment with transcutaneous electrical acupoint stimulation on the quality of recovery after ambulatory breast surgery: a prospective, randomised controlled trial. Anaesthesia. 2014;69(8):832–9.
- Zhou J, Chi H, Cheng TO, et al. Acupuncture anesthesia for open heart surgery in contemporary China. Int J Cardiol. 2011;150(1):12–6.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.